Monthly oncology bulletin — November 4, 2026
Colleagues: this issue covers October 5 to November 4, 2026; one item dated before that window is flagged as outside the period. The month was dominated by the ESMO 2026 Congress (Madrid, October 23–27) and by several FDA oncology approvals. Several results come from congress presentations not yet published in peer-reviewed form and are flagged as such; three of them (DeLLphi-305, Krascendo 1, and SAFFRON) have already been published in NEJM, the six-year NATALEE follow-up in Annals of Oncology, HORIZON-Breast06 in JAMA, and UNION in The Lancet Oncology, as their labels indicate. Hematologic oncology had little news ahead of ASH. Several items come from outside North America and Western Europe (China, Australia, Brazil, and the Dominican Republic).
Common solid tumors
1. Tarlatamab plus durvalumab as maintenance in extensive-stage small cell lung cancer (DeLLphi-305)
[Congress and article] [International]
Open-label phase 3 trial of 563 randomized patients (282 vs 281) without progression after first-line platinum, etoposide, and durvalumab: tarlatamab (DLL3×CD3 bispecific) plus durvalumab vs durvalumab alone. In the interim phase 3 analysis, presented at ESMO and published simultaneously in NEJM, median overall survival was 21.1 vs 12.7 months (hazard ratio for death 0.42; 95% CI 0.32–0.54); 12-month OS 79% vs 53%; PFS 7.4 vs 1.9 months (HR 0.34; 95% CI 0.28–0.42). Presented as LBA3 in Presidential Symposium I. The trial is sponsored by Amgen, with partial funding and durvalumab provided by AstraZeneca.
Why it matters: a survival gain of large magnitude in maintenance for this disease that could change practice; but it is an interim analysis of an open-label trial, presented at ESMO and published in NEJM, and the drug requires monitoring for cytokine release syndrome and neurotoxicity, which is difficult outside referral centers in the Dominican Republic.
Sources
- [Coverage] Targeted Oncology, October 24, 2026. https://www.targetedonc.com/view/esmo-2026-presidential-symposium-i-late-breaking-recap
- [Article] Pérol M, Yoshida T, Ahn MJ, et al. "Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer." N Engl J Med. 2026. DOI: 10.1056/NEJMoa2609482. https://www.nejm.org/doi/full/10.1056/NEJMoa2609482
- [Coverage] The ASCO Post, October 29, 2026. https://ascopost.com/news/october-2026/tarlatamab-plus-durvalumab-as-first-line-maintenance-in-extensive-stage-sclc/
2. Divarasib vs a pooled control group, mostly sotorasib, in KRAS G12C non-small cell lung cancer (Krascendo 1)
[Congress and article] [International]
Open-label phase 3, 338 randomized (167 vs 171) previously treated patients (platinum and a PD-(L)1 inhibitor) naive to KRAS G12C inhibitors: divarasib 400 mg daily vs a pooled control group treated with a first-generation KRAS G12C inhibitor (sotorasib in 156 patients and adagrasib in 15). In Krascendo 1, divarasib prolonged progression-free survival versus the pooled control group, which consisted mostly of patients receiving sotorasib (9.8 vs 5.7 months; HR 0.58; 95% CI 0.44–0.76); OS at the first interim analysis 17.7 vs 12.0 months (HR 0.56; 95% CI 0.41–0.78); confirmed ORR 58% vs 32%. Presented as LBA5 at ESMO and published in NEJM on October 25, 2026. F. Hoffmann-La Roche funded the trial.
Why it matters: a randomized comparison against first-generation KRAS G12C inhibitors with an overall survival benefit at an interim analysis; but the result was obtained against a pooled control arm made up mostly of sotorasib (only 15 patients received adagrasib), so it does not demonstrate superiority over each comparator separately, particularly adagrasib; in addition, the trial is open-label, and neither drug is widely available in the Dominican public system.
Sources
- [Coverage] Targeted Oncology, October 25, 2026. https://www.targetedonc.com/view/esmo-2026-savolitinib-presidential-symposium-divarasib-nsclc-krascendo1-saffron-clarity-gastric01-harmoni-gi1
- [Article] Skoulidis F, Ahn MJ, Gadgeel S, et al. "Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC." N Engl J Med. 2026. DOI: 10.1056/NEJMoa2605703. https://www.nejm.org/doi/full/10.1056/NEJMoa2605703
3. Osimertinib plus savolitinib after progression on osimertinib in EGFR-mutant NSCLC with MET alteration (SAFFRON)
[Congress and article] [China / international]
Open-label phase 3, 338 randomized patients (171 vs 167) with locally advanced or metastatic EGFR-mutated NSCLC with MET overexpression (3+ staining in ≥90% of tumor cells), MET amplification (≥10 gene copies by FISH), or both, after progression during osimertinib, confirmed centrally on a biopsy; osimertinib plus savolitinib vs platinum-pemetrexed. PFS 7.6 vs 5.4 months (HR 0.55; 95% CI 0.42–0.72); OS 17.8 vs 12.9 months (HR 0.68; 95% CI 0.50–0.91; 53% maturity). Presented by Shun Lu (Shanghai Chest Hospital) as LBA6 and published in NEJM on October 25, 2026. AstraZeneca funded the trial.
Why it matters: a chemotherapy-free option that outperformed chemotherapy in this MET-altered subgroup; it requires a postprogression biopsy and MET testing (IHC or FISH), which limits use where such testing is not routine.
Sources
- [Coverage] Targeted Oncology, October 25, 2026. https://www.targetedonc.com/view/esmo-2026-savolitinib-presidential-symposium-divarasib-nsclc-krascendo1-saffron-clarity-gastric01-harmoni-gi1
- [Article] Lu S, Girard N, Yang JC, et al. "Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy." N Engl J Med. 2026. Online ahead of print. DOI: 10.1056/NEJMoa2611335. https://www.nejm.org/doi/full/10.1056/NEJMoa2611335
4. Adjuvant ribociclib: descriptive overall survival signal in HR+/HER2− early breast cancer (NATALEE)
[Congress and article] [International]
Open-label phase 3 in stage II–III HR+/HER2− early breast cancer at risk of recurrence under the trial's eligibility criteria. The six-year analysis showed a descriptive overall survival signal. At a median follow-up of 66.5 months, ribociclib 400 mg for 3 years plus a nonsteroidal aromatase inhibitor vs the aromatase inhibitor alone: OS HR 0.809 (95% CI 0.661–0.989; nominal one-sided P = .019), 6-year OS 91.9% vs 89.7%; iDFS HR 0.741 (95% CI 0.646–0.849), 83.2% vs 77.9% at 6 years. Presented as LBA25 at ESMO and published in Annals of Oncology.
Why it matters: the absolute survival difference is about 2 points and the P value is nominal, so it should be read cautiously; it supports use in the trial population, but the cost of three years of a CDK4/6 inhibitor is the real barrier in our setting.
Sources
- [Coverage] Targeted Oncology, October 27, 2026. https://www.targetedonc.com/view/esmo-2026-breast-cancer-late-breaking-adcs-ribociclib
- [Article] "Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial." Ann Oncol. 2026. PMID: 42918423. https://pubmed.ncbi.nlm.nih.gov/42918423/
5. Darolutamide added to radiotherapy and ADT in very high-risk localized prostate cancer (DASL-HiCaP)
[Congress] [Australia / international]
International double-blind placebo-controlled phase 3, 1,106 randomized patients (primary or salvage radiotherapy); interim analysis. Metastasis-free survival HR 0.42 (95% CI 0.27–0.66); 4-year MFS 95% vs 88%. Overall survival follow-up is ongoing. A trial of the Australian ANZUP cooperative group (ANZUP1801), funded by Bayer, presented as LBA4.
Why it matters: the metastasis benefit is clear but OS is not yet; the effect in the salvage radiotherapy subgroup needs clarification; this is a cooperative-group trial funded by Bayer.
Sources
- [Coverage] Targeted Oncology, October 24, 2026. https://www.targetedonc.com/view/esmo-2026-presidential-symposium-i-late-breaking-recap
- [Official release] Bayer, October 24, 2026. https://www.bayer.com/media/download/e13c4502-52ce-439a-9403-4b79545fb29b/2026-0177e.pdf Copy on BioSpace (Business Wire): https://www.biospace.com/press-releases/esmo-2026-nubeqa-darolutamide-plus-adt-and-radiation-therapy-reduces-risk-of-metastasis-or-death-by-58-in-prostate-cancer-patients-at-high-risk-of-recurrence
- [Official release] ANZUP, media release on DASL-HiCaP. https://anzup.org.au/story/media-release-australian-led-global-trial-reports-new-treatment-prevents-relapse-of-very-high-risk-local-and-locally-advanced-prostate-cancer/
6. Ivonescimab plus chemotherapy beats durvalumab plus chemotherapy in biliary tract cancer (HARMONi-GI1)
[Congress] [China]
Double-blind phase 3 in patients enrolled only in China with first-line advanced biliary tract cancer: ivonescimab (PD-1/VEGF bispecific) with gemcitabine-cisplatin vs durvalumab with the same backbone. At the interim analysis, OS 14.9 vs 12.1 months (HR 0.75; 95% CI 0.61–0.92); PFS 8.4 vs 5.8 months (HR 0.61; 95% CI 0.51–0.72); ORR 53.8% vs 32.5%. Presented in Presidential Symposium II. According to Akeso's release, China's NMPA proposes to grant priority review; the drug is not approved in this indication.
Why it matters: according to Summit Therapeutics, Akeso's partner, it is the first known phase 3 in advanced biliary tract cancer to show OS superiority over an anti-PD-(L)1 plus chemotherapy regimen; but the population was exclusively Chinese and the analysis is interim; replication in Western and Latin American populations is needed before extrapolating.
Sources
- [Coverage] 10jqka (in Chinese; reproduces Akeso's release), October 25, 2026. https://news.10jqka.com.cn/20261025/c681058680.shtml
- [Official release] Akeso, October 25, 2026. https://www.prnewswire.com/news-releases/positive-overall-survival-results-from-the-phase-iii-harmoni-gi1-trial-of-ivonescimab-plus-chemotherapy-versus-durvalumab-plus-chemotherapy-in-first-line-biliary-tract-cancer-presented-at-the-esmo-2026-presidential-symposium-302918768.html
- [Official release] Summit Therapeutics, October 25, 2026. https://s206.q4cdn.com/652410165/files/doc_news/Ivonescimab-Plus-Chemotherapy-Demonstrates-Overall-Survival-Superiority-Compared-to-Durvalumab-Plus-Chemotherapy-in-First-Line-Treatm-603SN.pdf
- [Coverage] Targeted Oncology, October 25, 2026. https://www.targetedonc.com/view/esmo-2026-savolitinib-presidential-symposium-divarasib-nsclc-krascendo1-saffron-clarity-gastric01-harmoni-gi1
7. Three FDA solid tumor approvals: adjuvant atezolizumab in dMMR colon cancer, maintenance tucatinib in HER2+ breast cancer, and talazoparib in HRR-mutated metastatic prostate cancer
[Regulatory FDA] [USA]
October 8: atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III mismatch repair–deficient colon cancer (ATOMIC, open-label, 712 patients; DFS HR 0.50; 95% CI 0.35–0.73). October 7: tucatinib plus trastuzumab and pertuzumab as maintenance after induction in adults with unresectable locally advanced or metastatic HER2-positive breast cancer (HER2CLIMB-05, double-blind placebo-controlled, 654 patients; PFS 24.9 vs 16.3 months; HR 0.64; 95% CI 0.51–0.80). October 26: talazoparib plus enzalutamide in adults with metastatic androgen pathway modulation–naïve or –sensitive prostate cancer with an HRR gene mutation detected by an FDA-authorized test (TALAPRO-3, double-blind placebo-controlled, 599 patients; rPFS HR 0.48; 95% CI 0.36–0.65; OS immature).
Why it matters: ATOMIC is practice-changing and makes MMR testing mandatory in all stage III colon cancer; tucatinib and talazoparib still lack mature OS data, and talazoparib requires an FDA-authorized genomic test.
Sources
- [Regulator] FDA, approval notice for atezolizumab in stage III dMMR colon cancer, October 8, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer
- [Regulator] FDA, approval notice for tucatinib with trastuzumab and pertuzumab as maintenance, October 7, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer
- [Regulator] FDA, approval notice for talazoparib with enzalutamide, October 26, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive
Immunotherapy, antibody-drug conjugates, and targeted therapy
8. Chinese anti-HER2 ADC vs chemotherapy in HER2-low breast cancer (HORIZON-Breast06)
[Congress and article] [China]
HORIZON-Breast06 (open-label phase 3 at 73 hospitals in China, published in JAMA on October 23, 2026): trastuzumab rezetecan (SHR-A1811) vs physician's-choice chemotherapy in 551 randomized HER2-low patients (277 vs 274) with no more than one prior chemotherapy line for metastatic disease; PFS 16.4 vs 6.8 months (HR 0.27; 95% CI 0.21–0.34; P < .001), according to the article.
Why it matters: a very large effect size, but against chemotherapy rather than trastuzumab deruxtecan, the HER2-low standard; its main interest for the region will be price if it reaches the Latin American market.
Sources
- [Coverage] Targeted Oncology, October 27, 2026. https://www.targetedonc.com/view/esmo-2026-breast-cancer-late-breaking-adcs-ribociclib
- [Article] Fan Y, Liu Y, Wang Y, et al. "Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial." JAMA. 2026. DOI: 10.1001/jama.2026.21372. Subscription (free abstract). https://pubmed.ncbi.nlm.nih.gov/42925007/
9. Sonesitatug vedotin, a claudin 18.2 ADC, in previously treated gastric cancer (CLARITY-Gastric01)
[Congress] [International]
Phase 3 in CLDN18.2-positive (≥25% staining) gastroesophageal adenocarcinoma: in the main population, 267 patients received 2.2 mg/kg every 3 weeks and 265 received investigator's choice of therapy, which could include chemotherapy or targeted therapy depending on region. An international open-label trial with an initial dose-selection stage (an initial 1.8 mg/kg arm was closed); according to AstraZeneca's release, it is being conducted at 175 centers in 19 countries across North America, Europe, South America, and Asia. OS in third and later lines and centrally reviewed PFS in second and later lines were co-primary endpoints. OS in the 2L+ population was secondary. According to the same release, in third line or later, OS 10.0 vs 5.0 months (HR 0.47); in the ITT (2L+) population, 10.6 vs 6.4 months (HR 0.58). Centrally reviewed PFS was not significant (4.2 vs 3.8 months; HR 0.77; P = .053). Presented by Rui-Hua Xu (Sun Yat-sen University Cancer Center).
Why it matters: supports further evaluation of another CLDN18.2-directed strategy, distinct from zolbetuximab, relevant to a cancer with a high burden in Latin America; the PFS miss and open-label design call for caution.
Sources
- [Coverage] Targeted Oncology, October 25, 2026. https://www.targetedonc.com/view/esmo-2026-savolitinib-presidential-symposium-divarasib-nsclc-krascendo1-saffron-clarity-gastric01-harmoni-gi1
- [Official release] AstraZeneca, October 25, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/sonesitatug-vedotin-reduced-the-risk-of-death-by-42-pct-in-2nd-and-later-line-cldn182-positive-advanced-gastricgej-cancers-in-clarity-gastric01.html
10. Immunotherapy every 12 weeks: noninferiority not established and study stopped (MOIO)
[Congress] [Europe]
Academic phase 3 trial in 340 patients with advanced or metastatic solid tumours responding after 6 months of immunotherapy: standard dosing versus administration every 12 weeks. According to Institut Paoli-Calmettes, interim analyses did not establish noninferiority or permit a formal conclusion of inferiority; an overall-survival signal led the independent committee to recommend stopping the study.
Why it matters: an important negative result for health systems seeking savings through extended dosing; according to the authors, neither noninferiority nor definitive inferiority can be formally concluded, and early stopping limits precision, but it currently does not support 12-week spacing outside trials.
Sources
- [Coverage] Targeted Oncology, October 26, 2026. https://www.targetedonc.com/view/esmo-2026-presidential-symposium-iii-artemis-011-trofuse-005-keynote-c93-moio
- [Official release] Institut Paoli-Calmettes, notice on the MOIO study at ESMO 2026, in French. https://www.institutpaolicalmettes.fr/esmo-2026-etude-moio-gwenaelle-gravis/
11. Individualized mRNA vaccine plus pembrolizumab in resected melanoma (INTerpath-001)
[Congress] [International]
Double-blind phase 3, 1,137 patients randomized (2:1) with resected stage IIB–IV melanoma: intismeran autogene plus pembrolizumab vs placebo plus pembrolizumab. At the first interim analysis, RFS HR 0.58 (95% CI 0.45–0.75); 82.2% vs 70.0% at 24 months. Overall survival data remain immature. Presented as LBA1.
Why it matters: a positive phase 3 of a personalized neoantigen vaccine; but this is an interim analysis, and individual manufacturing makes near-term access in the region unlikely.
Sources
- [Coverage] Targeted Oncology, October 24, 2026. https://www.targetedonc.com/view/esmo-2026-presidential-symposium-i-late-breaking-recap
- [Official release] Merck, October 22, 2026. https://www.merck.com/?p=3701252
12. Accelerated approval of dostarlimab in dMMR/MSI-H locally advanced rectal cancer (AZUR-1)
[Regulatory FDA] [USA]
October 19: accelerated approval for adults with stage II–III locally advanced rectal cancer that is dMMR or MSI-H as determined by an FDA-authorized test. In AZUR-1 (open-label single-arm phase 2, 154 treated), the 12-month sustained clinical complete response rate by independent central review was 47% (n = 116 evaluable) and 68% by investigator (n = 144); in the 50-patient supporting study, the 12-month sustained clinical complete response rate was 93%, and among the 27 patients followed for at least 3 years there was one local recurrence. With a median follow-up of 26.3 months in AZUR-1, none of the patients with a clinical complete or near-complete response experienced disease progression. In AZUR-1, 110 of 154 patients (71%) received dostarlimab alone and did not experience progression. Twenty-six (17%) underwent surgery.
Why it matters: supports organ preservation without radiotherapy or surgery in adults with rectal tumors with this profile; organ preservation requires selecting patients who achieve a clinical complete response and monitoring them closely; an accelerated approval based on single-arm trials, and it requires MMR testing at diagnosis.
Sources
- [Regulator] FDA, accelerated approval notice for dostarlimab in locally advanced rectal cancer, October 19, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer
Hematologic oncology
13. First-line pirtobrutinib in chronic lymphocytic leukemia without 17p deletion
[Regulatory FDA] [USA] [Outside the period: October 2]
The FDA approved pirtobrutinib, a noncovalent BTK inhibitor, for untreated CLL/SLL without known 17p deletion, based on BRUIN CLL-313 (open-label, 282 patients) vs bendamustine-rituximab: median PFS not reached vs 33.5 months (HR 0.20; 95% CI 0.11–0.37); according to the article by Jurczak et al. in the Journal of Clinical Oncology, 24-month PFS 93.4% vs 70.7%. This approval was already covered in the October 4 issue.
Why it matters: the comparator (bendamustine-rituximab) is no longer standard in many countries, so the trial does not clarify its place relative to other BTK inhibitors or venetoclax. The major hematologic oncology data are expected at ASH in December.
Sources
- [Regulator] FDA, approval notice for pirtobrutinib in untreated CLL/SLL, October 2, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic
- [Article] Jurczak et al. "BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma." J Clin Oncol. DOI: 10.1200/JCO-25-02380. https://ascopubs.org/doi/10.1200/JCO-25-02380
- [Coverage] Pharmacy Times, October 30, 2026. https://www.pharmacytimes.com/view/october-2026-in-hematology-5-updates-shaping-the-profession
Screening, prevention, supportive care, radiotherapy, surgery, and access
14. Short-course radiotherapy plus camrelizumab and CAPOX vs long-course chemoradiotherapy in locally advanced rectal cancer (UNION)
[Congress and article] [China]
Phase 3, 231 randomized patients (113 vs 118). Experimental arm: 25 Gy in 5 fractions, 2 cycles of CAPOX with camrelizumab, surgery, and 6 cycles of adjuvant CAPOX with camrelizumab, followed by camrelizumab alone for up to one year of treatment. Control arm: 50.4 Gy in 28 fractions with capecitabine, 2 cycles of CAPOX, surgery, and 6 cycles of adjuvant CAPOX without camrelizumab. The primary endpoint, pathologic complete response, had already been met (39.8% vs 15.3%; ESMO 2023). The prespecified interim event-free survival analysis, published online in The Lancet Oncology on October 25, 2026, showed 3-year event-free survival of 91.3% versus 77.4% (HR 0.33; 95% CI, 0.15–0.71), a secondary endpoint. A trial at Chinese centers funded by Jiangsu Hengrui.
Why it matters: short-course radiotherapy saves weeks of machine time, a scarce resource in the Dominican Republic; but the arms differ in radiotherapy and in perioperative camrelizumab, so the benefit cannot be attributed to short-course radiotherapy alone; in addition, the trial is modest in size, industry-funded, and EFS was a secondary endpoint.
Sources
- [Article] Tao K, Lin Z, Zhang P, et al. "Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial." Lancet Oncol. 2026;27(11):1437–1449. DOI: 10.1016/S1470-2045(26)00446-8. https://pubmed.ncbi.nlm.nih.gov/42927765/
- [Coverage] OncoDaily, October 26, 2026. https://oncodaily.com/oncolibrary/radiotherapy/union-phase-iii-trial
- [Meeting] ESMO Congress 2023, abstract LBA25, October 21, 2023. https://oncologypro.esmo.org/meeting-resources/esmo-congress/neoadjuvant-short-course-radiotherapy-followed-by-camrelizumab-plus-chemotherapy-versus-long-course-chemoradiotherapy-followed-by-chemotherapy-in-l
15. Dominican Republic: 11 provinces with no mammograms recorded in the public network, January–August 2026
[Publication] [Dominican Republic]
A journalistic analysis by El Dinero of National Health Service (SNS, RIESS) data counts 20,784 bilateral mammograms in the public network from January to August 2026, 62% in the Distrito Nacional and Santo Domingo province, and none recorded in 11 provinces, against 1.27 million women aged 40–69 in the subsidized regime. The 2026 budget for the Early Detection and Cancer Care program is RD$499.3 million. It cites about 2,609 annual breast cancer diagnoses (Ministry of Public Health) and that 65% are diagnosed at advanced stages (INCART figure from 2023).
Why it matters: not a scientific study, and missing records do not prove missing studies. The records show a geographic gap in public-sector screening. This analysis cannot determine how much it contributes to late diagnosis.
Sources
- [Coverage] El Dinero, October 19, 2026. https://eldinero.com.do/385472/gobierno-destina-rd499-3-millones-a-deteccion-del-cancer-pero-11-provincias-no-registran-mamografias/
Cross-cutting
16. ANVISA approves telisotuzumab vedotin in NSCLC with high c-Met overexpression
[Regulatory ANVISA] [Brazil]
According to ANVISA's October 20, 2026 notice, the Brazilian agency approved the registration of this anti-c-Met ADC (Emrelis) for adults with locally advanced or metastatic nonsquamous NSCLC, EGFR wild-type, with high c-Met protein overexpression and prior systemic therapy, based on the pivotal phase 2 LUMINOSITY study: ORR 29.2% in the total evaluated population and 34.5% with high overexpression. In the same notice, the agency also announced the registration of Poherdy (pertuzumab).
Why it matters: an approval based on a phase 2 study whose cited data are response rates, without comparative survival data; it requires validated c-Met IHC.
Sources
- [Regulator] ANVISA, notice on the approval of Emrelis (telisotuzumab vedotin), in Portuguese, October 20, 2026. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-aprova-novo-medicamento-para-cancer-de-pulmao-avancado-1 English version of the notice: https://www.gov.br/anvisa/en/updates/anvisa-approves-new-drug-for-advanced-lung-cancer
Upcoming meetings and dates
- American Society of Hematology Annual Meeting (ASH 2026), December 12–15, in New Orleans and online: confirm dates at hematology.org.
- San Antonio Breast Cancer Symposium (SABCS 2026), December 8–11: confirm dates at sabcs.org.
Ready-to-paste LinkedIn post
Monthly oncology bulletin — November 4, 2026 16 verified items from the past month: ESMO 2026, FDA approvals, ANVISA, and access data from the Dominican Republic. Three worth your time: • DeLLphi-305: tarlatamab plus durvalumab maintenance in extensive-stage SCLC raised median OS from 12.7 to 21.1 months (HR 0.42). Interim analysis, open-label; presented at ESMO and published in NEJM. • MOIO, immunotherapy spaced to every 12 weeks: It did not establish noninferiority, and a survival signal prompted early stopping. • HARMONi-GI1: ivonescimab plus chemotherapy beat durvalumab plus chemotherapy in biliary tract cancer (OS 14.9 vs 12.1 months). Chinese population only, interim analysis. Full bulletin, with a critical appraisal of each study and links to its sources: https://boletinesmedicos.com/en/oncology/2026-11-04.html #Oncology #Cancer #ESMO2026 #LungCancer #Immunotherapy
Ready-to-paste X (Twitter) post
ESMO 2026 and NEJM: tarlatamab maintenance extends survival in extensive-stage SCLC (21.1 vs 12.7 mo; HR 0.42; interim analysis). MOIO, 12-weekly immunotherapy: It did not establish noninferiority, and a survival signal prompted early stopping. Bulletin: https://boletinesmedicos.com/en/oncology/2026-11-04.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.